Latitude, Seasonality, and Circadian Determinants of Outcomes of Systemic Cancer Therapy: Evidence from Chemotherapy, Immunotherapy, and Chemo-Immunotherapy Combinations. A Systematic Review.
Giving immunotherapy in the morning and adjusting chemotherapy timing to body rhythms may improve survival and reduce side effects in cancer patients.
Morning/early daytime ICI administration associated with longer OS/PFS in retrospective cohorts; chronomodulated chemotherapy consistently reduced toxicity and sometimes improved response/TTP; vitamin D supplementation during immunotherapy associated with improved survival; objective circadian disruption repeatedly associated with poorer prognosis. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- PRISMA 2020 systematic review (n=35 studies: 6 RCTs, 2 patient-level meta-analyses, 5 prospective cohorts, 22 retrospective cohorts)
- Category
- novel_therapeutics
- Maturity
- Potentially Practice-Changing
- Journal
- Critical Reviews in Oncology/Hematology
Why it surfaced
Systematic review with RCT-level evidence on modifiable variable (treatment timing, vitamin D) affecting immunotherapy outcomes; Crit Rev Oncol/Hematol; immediately actionable chronotherapy-ICI hypothesis for prospective testing.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.